Documents

Revenue rose to ₹22,211 million, led by Radiopharma and injectables; net profit declined sequentially.

FY 2026 revenue up 14%, with margin recovery expected in H2 FY 2027 as new capacity ramps.

Q3'FY26 revenue up 17% YoY, with strong growth in CDMO and CRDMO; Vision 2030 targets on track.

Q2'FY26 delivered double-digit revenue growth and margin expansion, supporting Vision 2030 goals.

Q1'FY26 saw double-digit revenue growth, margin gains, and strong progress toward Vision 2030.

Robust FY25 growth with 24% EBITDA rise, strong cash flow, and Vision 2030 momentum.

Q3'FY25 delivered robust growth, margin expansion, and improved leverage across all key segments.

Q2'FY25 delivered higher income, margin expansion, and a turnaround in Generics.

Q1 FY25 saw strong revenue and EBITDA growth, reduced leverage, and major PET network investment.